Data from the ALSPAC cohort is available to researchers according to processes outlined at <http://www.bristol.ac.uk/alspac/researchers/access/> and is consistent with the data-sharing policies of PLOS. Individual level data have restricted access and are distributed upon approval of research proposal and payment of data access costs.

Introduction {#sec001}
============

Previous research has clearly established a link between early environments (prenatal and postnatal), genetic and behavioral factors on the developmental origins of health and disease (DOHaD) \[[@pgen.1008790.ref001]\]. Among environmental factors, breastfeeding has been advocated in the prevention of overweight/obesity among children. The WHO suggests breastfeeding is the "perfect food for the newborn" and recommends all infants be exclusively breastfed up to 6 months of age, with continued breastfeeding along with appropriate complementary foods up to two years of age or beyond \[[@pgen.1008790.ref002]\]. Importantly, there is growing evidence that breastfeeding may reduce the risk of being overweight \[[@pgen.1008790.ref003]\]. A large meta-analysis from WHO showed that the odds of being obese among children who never breastfed or breastfed for less than 6 months vs. those who breastfed for at least 6 months were 1.22 (95% CI, 1.16 to1.28) for non-exclusive breastfeeding and 1.25 (95% CI, 1.17 to1.36) for EBF \[[@pgen.1008790.ref004]\]. Despite numerous observational studies demonstrating the benefits of breastfeeding on a healthy infant growth, the biological functions underlying this effect are still poorly understood. It also remains unclear whether the beneficial effect of breastfeeding extends to children with higher genetic risks. Our previous analysis of the ALSPAC child cohort suggested that a longer duration of EBF (i.e. at least 5 months) has significant preventive effect on BMI growth trajectories among children carrying a genetic variant in the *FTO* gene \[[@pgen.1008790.ref005]\]. Recently, a large GWAS based on 339,224 adult Caucasians identified 97 genetic variants strongly associated with BMI and explaining about 2.7% of BMI variability, which can be used to construct a GRS predictive of adult and children obesity-related traits \[[@pgen.1008790.ref006]\]. This 97-SNPs GRS has been found to be associated with BMI across all ages in adults, with stronger associations in women than in men. This sex difference could reflect a greater heritability of adult BMI in women than in men, as reported in twin studies, or that different sets of genes influence adult BMI in men and women \[[@pgen.1008790.ref007]--[@pgen.1008790.ref009]\]. In terms of effect size, a 10-allele increment in the weighted GRS increases BMI by 1.35 kg/m^2^ in women and 0.91 kg/m^2^ in men, at 45 years of age \[[@pgen.1008790.ref010]\]. In children, a similarly defined GRS was found associated with BMI at adiposity peak and childhood BMI, where a one-allele increment in the GRS increases BMI around 6 years of age by 0.112 kg/m^2^ \[[@pgen.1008790.ref011]\]. This GRS explained about 1.5% of child BMI variability at 6 years of age. Our previous work has shown that the effect of the GRS on pediatric BMI starts in early childhood and continues through adulthood \[[@pgen.1008790.ref012]\]. While knowledge on the genetic architecture of adult and pediatric BMI is accumulating thanks to large-scale GWAS results, the construction of obesity-specific GRSs is emerging as an important approach for the personal and clinical management of individuals at risk of adverse outcomes \[[@pgen.1008790.ref013], [@pgen.1008790.ref014]\]. It is therefore timely to consider the protective effect of EBF among children with elevated risk of overweight/obesity, where this risk is assessed by an obesity-specific GRS, and thus to extend our previous results on the *FTO* genetic variant. Our goal in this paper is to assess the effect of this GRS from infancy to the end of adolescence as well as the modulating effect of EBF during this time period.

Methods {#sec002}
=======

Ethics statement {#sec003}
----------------

Ethical approval for the study was obtained from the ALSPAC Law and Ethics committee and our Local Research Ethics Board. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Please note that the study website contains details of all the data that are available through a fully searchable data dictionary and variable search tool \[[@pgen.1008790.ref015]\]. Patients or the public WERE NOT involved in the design, or conduct, or reporting, or dissemination plan of our research.

Cohort information {#sec004}
------------------

Our discovery cohort is the Avon Longitudinal Study of Parents and Children (ALSPAC) \[[@pgen.1008790.ref016], [@pgen.1008790.ref017]\]. Pregnant women resident in Avon, UK with expected dates of delivery 1st April 1991 to 31st December 1992 were invited to take part in the study. The core ALSPAC sample consists of 14,541 pregnancies. An additional 542 eligible pregnancies not in the core sample, who were invited to participate at age 7 and for whom research data were available in November 2004, were also included in our study. Overall, these 15,083 pregnancies resulted in 15,224 known fetuses. For reasons of confidentiality data on the 13 triplet and quadruplet children were not available for analysis. After removing children without anthropometric measures (height/length or weight, n = 2,462), non-Caucasian children (n = 2,314), those without genotype data (n = 3,537) or without exclusive breastfeeding (n = 857) or socio-economic information (n = 775), a total of 2,690 boys and 2,576 girls (N = 5,266) was available for our analyses. These children have been followed for over two decades. The description of the cohort is given in [Table 1](#pgen.1008790.t001){ref-type="table"}.

10.1371/journal.pgen.1008790.t001

###### Summary statistics for individual level variables and BMI measurements by age in years.

Chi-square or two-sample t-test was carried out to examine differences between boys and girls for individual level variables.

![](pgen.1008790.t001){#pgen.1008790.t001g}

                                                                       Individual-level variables   BMI measurement by age                                                 
  -------------------------------------------------------------------- ---------------------------- ------------------------ ---------- -------- ------ ----------- ------ -----------
  *Categorical Variables*                                              **N(%)**                     **N(%)**                                                               
  Mother's Education                                                                                                                    Birth    2013   13.9(1.8)   1947   13.8(1.7)
   CSE/none                                                            313 (11.6%)                  303 (11.8%)              0.734      1        716    18.0(1.4)   665    17.7(1.4)
   Vocational                                                          227 (8.4%)                   193 (7.5%)                          2        638    17.1(1.3)   591    16.8(1.4)
   O Level                                                             955 (35.5%)                  904 (35.1%)                         3        641    16.6(1.3)   601    16.5(1.5)
   A Level                                                             720 (26.8%)                  711 (27.6%)                         4        676    16.4(1.3)   634    16.3(1.6)
   Degree                                                              475 (17.7%)                  465 (18.1%)                         5        719    16.0(1.6)   682    16.0(1.7)
  Mother's pregnancy smoking status                                                                                                     6        1898   15.7(1.6)   1796   15.6(1.8)
   Never                                                               1493 (55.5%)                 1450 (56.3%)             0.388      7        1361   16.1(1.9)   1286   16.3(2.1)
   No during pregnancy                                                 691 (25.7%)                  679 (26.4%)                         8        1819   16.4(2.0)   1790   16.7(2.2)
   Yes during pregnancy                                                506 (18.8%)                  447 (17.4%)                         9        1074   17.0(2.3)   1044   17.4(2.5)
  Mean family income per week                                                                                                           10       2917   17.6(2.8)   3006   17.9(2.9)
   \< £100                                                             45 (1.7%)                    48 (1.9%)                0.634      11       1338   18.1(3.0)   1281   18.4(3.1)
   \< £200                                                             329 (12.2%)                  309 (12.0%)                         12       2044   18.9(3.3)   2119   19.2(3.3)
   \< £300                                                             479 (17.8%)                  473 (18.4%)                         13       1675   19.4(3.4)   1750   20.0(3.4)
   \< £400                                                             1038 (38.6%)                 946 (36.7%)                         14       1745   19.9(3.3)   1826   20.6(3.4)
   ≥ £400                                                              799 (29.7%)                  800 (31.1%)                         15       1058   20.9(3.3)   1116   21.6(3.5)
                                                                                                                                        16       449    21.1(3.3)   512    21.8(3.5)
  *Continuous Variables*                                               **Mean (SD)**                **Mean (SD)**                       17       226    22.2(3.5)   273    22.2(3.6)
  Mother's pre-pregnancy BMI                                           23.0 (3.8)                   22.9 (3.8)               0.353      18       989    22.5(3.9)   1236   22.9(4.1)
  Duration of EBF (month) [^a^](#t001fn001){ref-type="table-fn"}       1.6 (1.56)                   1.7 (1.59)               0.004      19--20   67     22.5(3.3)   79     23.2(4.0)
  Duration of BF (month) [^b^](#t001fn002){ref-type="table-fn"}        4.6 (4.71)                   4.9 (4.66)               0.090                                         
  Gestational age (weeks)                                              39.5 (1.8)                   39.6 (1.7)               0.006                                         
  GRS (Range 0--10)[^c^](#t001fn003){ref-type="table-fn"}              5.0 (1.3)                    5.0 (1.3)                0.520                                         
  GRS (number of risk alleles)[^d^](#t001fn004){ref-type="table-fn"}   95.3 (6.7)                   92.7 (7.1)               \<0.0001                                      
   (min, max)                                                          (73, 119)                    (68, 120)                                                              

^a^ Duration of EBF (exclusive breastfeeding in months).

^b^ Duration of BF (non-exclusive breastfeeding in months).

^c^ GRS (genetic risk score, deciles) were derived for boys and girls separately.

^d^ GRS in raw scales (number of risk alleles). 1-decile increase in the GRS corresponds to a 4.6-allele effect in boys and 5.2 allele-effect in girls.

Exclusive breastfeeding {#sec005}
-----------------------

Information pertaining to early infant feeding was collected. Mothers recorded the age at which breastfeeding was stopped (in months), and the age at which supplementation with milk other than breast milk was introduced (in months). This information was determined from the mother's diary of early feeding milestones, as well as from an interview with the study nurse at the 6-month child follow-up and survey questions at the 15-month child follow-up. The duration of EBF was defined as the provision of breastmilk only from the time of from birth until the introduction of other milk (non-breast milk) or any solid. Different coding strategies for EBF were assessed using either categorical or continuous variables. The most significant effect of EBF was obtained under a continuous coding, which can be interpreted as a dose-response relationship between BMI and EBF.

Genetic risk score {#sec006}
------------------

We used 69 SNPs associated with BMI at genome-wide significance in the Genetic Investigation of Anthropometric Traits (GIANT) consortium and that were recently included in a gene-obesogenic interaction study \[[@pgen.1008790.ref018]\] as well as 25 independent non-overlapping SNPs that we previously studied in relation to pediatric BMI trajectories to create a GRS of 94 SNPs ([S1 Table](#pgen.1008790.s002){ref-type="supplementary-material"}), which represents the genetic susceptibility to overweight and obesity \[[@pgen.1008790.ref012]\]. The sex-specific GRSs were created using the imputed dosages for the 94 SNPs where each SNP was recoded to represent the number of BMI-increasing alleles and was weighted using the sex-specific weights derived from the GIANT consortium and UK BiobBank meta-analysis \[[@pgen.1008790.ref019]\] and available through the portal: <https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files>. GRS scores were then created for boys and girls separately by scaling the sum of the weighted SNP effects (∑*β*~*i*~ × *SNP*~*i*~, *i* = 1, ..., 94) to a range of 0 to 10. With this transformation, a 1-unit (i.e. 1-decile) increase in the GRS corresponded to a 4.6-allele effect in boys and 5.2 allele-effect in girls.

Assessment of BMI and control variables {#sec007}
---------------------------------------

Birth length (crown-heel) was measured by ALSPAC staff who visited newborns soon after birth (median 1 day, range 1--14 days), using a Harpenden Neonatometer (Holtain Ltd). Birth weight was extracted from medical records. From birth to five years, length and weight measurements were extracted from health visitor records, which form part of standard childcare in the UK. In this cohort we had up to four measurements taken on average at six weeks and at 10, 21, and 48 months of age. For a random 10% of the cohort, we also have length/height measurements from eight research clinic visits, held between the ages of four months and five years of age. From age seven years upwards, all children were invited to annual clinics. In addition, parent-reported child height and weight were also available from the questionnaires. BMI was derived from height and weight measurements (mean 9 measurements per individual) and calculated as the weight (in kg) divided by the square of height (in cm). The following confounding variables consistently associated with breastfeeding were controlled in the analysis: gestational age (in months), maternal preconception BMI, education and smoking status, and family income. The gestational age was calculated based on a variety of records including last menstrual period, pediatric assessment, obstetric assessment and ultrasound assessment. Self-reported maternal preconception BMI was collected from the \"About Yourself\" questionnaire at 12 weeks of gestation. Maternal education status was obtained from the \"Your Pregnancy\" questionnaire administered at 32-weeks of gestation and coded as: Certificate of Secondary Education (CSE)/none; vocational; O level; A level and Degree. Maternal smoking status was collected from the \"Having a Baby\" questionnaire at 18-week gestation and was coded as: Never; Yes during pregnancy; Not during pregnancy. Family income was collected at the 33, 47, 85, 97, 134 months and 18 years follow-up visits and the mean weekly income was categorized into one of five levels: less than £100, £100--£199, £200--£299, £300--£399, and £400 per week or more. Gestational age and maternal preconception BMI were centered at the means and analyzed as continuous variables. The levels with the largest proportions for categorical variables were used as the reference groups in the analysis.

Statistical methods {#sec008}
-------------------

Summary statistics were used to describe the sample characteristics for boys and girls. A mixed-effects model approach with cubic splines of age ([S1 Text](#pgen.1008790.s001){ref-type="supplementary-material"}) was used to fit the longitudinal BMI data from the ALSPAC cohort from birth to 20 years of age in boys and girls separately \[[@pgen.1008790.ref020]\]. We examined three-way interactions between cubic splines of age, EBF and GRS. Both backward elimination and stepwise variable selections were used to select the best model and optimal spline knots. We calculated the predicted BMI trajectories (i.e., the population average) up to age 18 years with GRS scores evaluated at the three quartiles 2.5, 5.0 and 7.5 for zero and five months of EBF, respectively, to characterize the effect of GRS and EBF on BMI trajectories. Hypothesis testing of GRS and EBF effect at specific ages was performed by using the generalized linear hypothesis (GLM) approach ([S1 Text](#pgen.1008790.s001){ref-type="supplementary-material"}) \[[@pgen.1008790.ref021]\]. We also estimated the timing of adiposity peak (AP) and adiposity rebound (AR). The bootstrap method with 2,000 iterations was used to test the effect of GRS and EBF on AR and AP \[[@pgen.1008790.ref022]\]. Additionally, we replaced the EBF variable with non-exclusive BF to examine if EBF had stronger effect than any BF.

Statistical analyses were performed using the statistical software *R* 3.5.1. Statistical packages in R include "nlme", "effects", "spida2" and "ggplot2". All hypothesis tests were 2-sided and the priori level of significance was set at 5%.

Missing data {#sec009}
------------

Children with missing longitudinal BMI observations over time were included in our analyses as long as they had at least one BMI observation available between birth and 20 years. The estimation from mixed-effects models remains valid in that situation assuming the longitudinal observations are missing at random \[[@pgen.1008790.ref020]\].

Results {#sec010}
=======

Effect of the GRS on pediatric BMI growth trajectories {#sec011}
------------------------------------------------------

The GRS is associated with higher BMI with an increasing effect with age ([Fig 1](#pgen.1008790.g001){ref-type="fig"} and [S2 Table](#pgen.1008790.s003){ref-type="supplementary-material"}). A quartile (2.5 units) increment in the GRS increases BMI by 0.61 kg/m^2^ (95% CI, 0.47 to 0.75, *p*\<0.0001) at age 7 years and 1.98 kg/m^2^ (95% CI, 1.65 to 2.32, *p*\<0.0001) at age 18 years among boys. The corresponding effects in girls are 0.39 kg/m^2^ (95% CI, 0.24 to 0.55, *p*\<0.0001) and 0.75 kg/m^2^ (95% CI, 0.40 to 1.09, *p*\<0.0001). These effects become significant from 5 years of age.

![Marginal effect of 2.5 units increase in GRS on pediatric BMI from birth to 18 years of age for boys and girls.](pgen.1008790.g001){#pgen.1008790.g001}

Effect of GRS on the timing of adiposity peak (AP) and adiposity rebound (AR) {#sec012}
-----------------------------------------------------------------------------

The GRS had no significant effect on the age at AP but was negatively associated with the age at AR among boys and girls, where a higher level of GRS corresponds to earlier age at AR ([S3 Table](#pgen.1008790.s004){ref-type="supplementary-material"}). For instance, a GRS score of 5.0 vs. 2.5 (median vs. 1^st^ quartile) advances the age at AR by 0.36 years (95% CI, 0.37 to 0.46, *p*\<0.0001) and a GRS score of 7.5 vs. 2.5 (inter-quartile difference) by 0.65 years (95% CI, 0.49 to 0.80, *p*\<0.0001) in boys. These effects in girls are 0.31 year (95% CI, 0.21 to 0.41, *p*\<0.0001) and 0.57 year (95% CI, 0.39 to 0.741, *p*\<0.0001), respectively.

Effect of EBF on child longitudinal BMI by GRS levels {#sec013}
-----------------------------------------------------

Our results indicate a significant 3-way interaction between age, GRS and EBF (or BF) in boys and girls ([S4 Table](#pgen.1008790.s005){ref-type="supplementary-material"}). EBF has a stronger protective effect as the children become older and the effect is greater with increasing GRS ([Fig 2](#pgen.1008790.g002){ref-type="fig"}, [S5 Table](#pgen.1008790.s006){ref-type="supplementary-material"}). In boys, at the first quartile of GRS (GRS = 2.5), five-month EBF decreases BMI by 0.21 kg/m^2^ (*p* = 0.19) at 7 years and 0.81 kg/m^2^ (95% CI, 0.05 to 1.57, *p* = 0.0362) at 18 years. At the median GRS level (GRS = 5.0), this BMI decrease is 0.12 kg/m^2^ (*p* = 0.32) and 0.98 kg/m^2^ (95% CI, 0.40 to 1.56, *p* = 0.001). At the third quartile of GRS (GRS = 7.5), this decrease reaches 0.03 kg/m^2^ (*p* = 0.85) and 1.14 kg/m^2^ (95% CI, 0.37 to 1.91, *p* = 0.0037), respectively. In girls, five-month EBF decreases BMI by 0.38 kg/m2 (95% CI, 0.04 to 0.72, *p* = 0.0272) at 7 years and 0.86 kg/m^2^ (95% CI, 0.11 to 1.62, *p* = 0.0252) at 18 years at the first GRS quartile. This decrease reaches 0.50 kg/m^2^ (95% CI, 0.24 to 0.76, *p* = 0.0002) and 1.20 kg/m^2^ (95% CI, 0.62 to 1.77, *p*\<0.0001) at the median GRS level, 0.62 kg/m^2^ (95% CI, 0.28 to 0.96, *p* = 0.0003) and 1.53 kg/m^2^ (95% CI, 0.76 to 2.29, *p*\<0.0001) at the third quartile GRS level for age 7 and 18 respectively.

![Effect of 5 months of exclusive breastfeeding (EBF) and non-exclusive breastfeeding (BF) on BMI measurements at 7, 10 15 and 18 years of age for GRS scores evaluated at 2.5, 5.0 and 7.5.](pgen.1008790.g002){#pgen.1008790.g002}

Effect of 5 months EBF on timing of AP and AR by GRS levels {#sec014}
-----------------------------------------------------------

EBF to 5 months delays the age of AP significantly in boys with the average/high levels of GRS: 0.21 year (95% CI, 0.05 to 0.36, *p* = 0.0076) and 0.25 year (95% CI, 0.05 to 0.42, *p* = 0.0136) for GRS level of 5.0 and 7.5, respectively ([S6 Table](#pgen.1008790.s007){ref-type="supplementary-material"}). A shorter delay in the age at AP was observed in girls, i.e. 0.14 year (95% CI, 0.04 to 0.24, *p* = 0.0063) and 0.24 year (95% CI, 0.09 to 0.38, *p* = 0.0011), respectively. A duration of 5 months of EBF delays also the age at AR significantly in girls all levels of GRS, i.e. 0.64 years (95% CI, 0.15 to 1.16, *p* = 0.0114), 0.53 years (95% CI, 0.20 to 0.86, *p* = 0.0015), and 0.44 (95% CI, 0.05 to 0.85, *p* = 0.0278) for GRS of 2.5, 5.0 and 7.5, respectively. It delays also the age at AR in boys but to a lesser extent and not significantly.

Effect of non-exclusive BF on pediatric BMI growth trajectories {#sec015}
---------------------------------------------------------------

The effect of non-exclusive BF had less impact on BMI growth trajectories at different ages compared to the effect of EBF ([Fig 3](#pgen.1008790.g003){ref-type="fig"}, [S5 Table](#pgen.1008790.s006){ref-type="supplementary-material"}). For instance, at 18 years, the reduction of BMI associated with 5 months of non-exclusive BF varied in boys from 0.31 (95% CI, 0.05 to 0.56, *p* = 0.0172) to 0.37 (95% CI, 0.12 to 0.63, *p* = 0.0042) between the first and third GRS quartiles, and from 0.34 (95% CI, 0.09 to 0.60, *p* = 0.0075) to 0.54 (95% CI, 0.27 to 0.81, *p*\<0.0001) in girls.

![Predicted BMI growth trajectories for ALSPAC boys and girls from birth to age 18 years for GRS = 2.5 and 7.5, and (a) EBF = 0 or 5 months, and (b) BF = 0 or 5 months.](pgen.1008790.g003){#pgen.1008790.g003}

Dose-response relationship of EBF duration on pediatric BMI {#sec016}
-----------------------------------------------------------

As expected, a duration of EBF for 3 months had significantly less impact in decreasing BMI than 5 months of EBF ([S7 Table](#pgen.1008790.s008){ref-type="supplementary-material"}, [S1 Fig](#pgen.1008790.s009){ref-type="supplementary-material"}), and BF 3 month and 5 months had less effect compared to EXBF. At 18 years, the range of variation was -0.49 kg/m^2^ to -0.68 kg/m^2^ in boys and from -0.52 kg/m^2^ to -0.92 kg/m^2^ in girls, respectively, across the GRS categories ([Fig 4](#pgen.1008790.g004){ref-type="fig"}). A duration of 3-months EBF also had a decreased influence on delaying the age of AP and AR compared to a 5-months duration ([S6 Table](#pgen.1008790.s007){ref-type="supplementary-material"}). This is an important result since rapid weight gain during infancy is known to predispose to later onset of overweight and obesity during adulthood.

![Effect sizes of GRS on BMI and attenuation effects of 3 and 5 months of non-exclusive breastfeeding (BF) and exclusive breastfeeding (EBF) among ALSPAC boys and girls at 7, 10, 15 and 18 years.\
In each sub-figure are represented the GRS effect on BMI (first 2 bars from the left) and the attenuation effect of 3-months BF (second 2 bars from the left), 5-months BF (third 2 bars from the left), 3-months EBF (second 2 bars from the right) and 5-months EBF (last 2 bars from the right).](pgen.1008790.g004){#pgen.1008790.g004}

Discussion {#sec017}
==========

Our study demonstrates the role of the duration and exclusivity of breastfeeding in reducing BMI increases during childhood and adolescence resulting from adverse genetic effects. In the high genetic susceptible group (upper GRS quartile), EBF to 5 months reduces BMI by 1.14 kg/m^2^ (95% CI, 0.37 to 1.91, *p* = 0.0037) in 18-year-old boys, which compensates a 3.9-decile GRS increase. In 18-year-old girls, EBF to 5 months decreases BMI by 1.53 kg/m^2^ (95% CI, 0.76 to 2.29, *p*\<0.0001), which compensates a 7.0-decile GRS increase. EBF acts early in life by delaying the age at AP and at AR. Importantly, EBF to 3 months and non-exclusive breastfeeding to 5 months had a significantly less effect on BMI clearly demonstrating a strong dosage effect of continued EBF. These results reiterate the importance of EBF to 6 months as recommended by WHO.

The role of the obesity-specific GRS has been recently studied in children and adolescents \[[@pgen.1008790.ref010]--[@pgen.1008790.ref013], [@pgen.1008790.ref023]--[@pgen.1008790.ref028]\] and recent evidence suggests a continuum of risks starting from early childhood \[[@pgen.1008790.ref012]\] and rising up to the mid 40s \[[@pgen.1008790.ref010]\]. Our study confirms this trend and helps better characterize the GRS effect during childhood, showing a clear increasing trend from early infancy to late adolescence/early adulthood in boys and girls. Our results also shed light into the critical role of EBF in early development by showing how it delays the age at AP and AR and brings new insights by emphasizing that its effect in the high-susceptible genetic group is more substantial right after the timing of AR. During this developmental period, BMI is a strong predictor of later overweight/obesity development \[[@pgen.1008790.ref029]--[@pgen.1008790.ref031]\].

Recent efforts have demonstrated the clinical utility of the GRS in predicting overweight and obesity risks \[[@pgen.1008790.ref013], [@pgen.1008790.ref014]\]. A recent paper using an extended version of the GRS based on 2.1 million genetic variants, stressed the greatly increased risk of severe obesity among individuals in the top decile of the GRS. For instance, 15.6% of individuals in the top decile of GRS went on to develop severe obesity compared with 5.6% of those in deciles 2--9 and 1.3% in the lowest decile \[[@pgen.1008790.ref013]\]. This top decile of the population had also a 4.2, 6.6 and 14.4-fold increased risk of a high BMI of 40, 50 and 60 compared to the rest of the population and also had increased risks of cardiometabolic diseases and overall mortality. Targeting this 10% decile population might therefore offer a cost-efficient strategy to reduce obesity-related morbidity, although this would need to be thoroughly evaluated. These authors also stressed the importance of early intervention, acknowledging that "given that the weight trajectories of individuals in different GRS deciles start to diverge in early childhood, such interventions may have maximal effect when employed early in life." As noted also in Torkamani et. al. \[[@pgen.1008790.ref014]\], a targeted intervention might help "clarifying a high-risk individual's perception of their susceptibility to disease and quantifying the benefits of healthy behaviors could be an effective tool to induce and maintain behavioral changes".

Our study suffers from a number of limitations. Due to the relatively short duration of EBF in ALSPAC, we were not able to assess the effect of more than 5 months of EBF on pediatric BMI trajectories. Our GRS definition was based on 94 SNPs including 69 SNPs from Locke et.al., 2015 \[[@pgen.1008790.ref006]\]. As large meta-GWASs on BMI and obesity-related traits are fast developing, some extended definitions of GRSs are emerging such as Yengo et.al. 2018 \[[@pgen.1008790.ref019]\] and Khera et.al, 2019 \[[@pgen.1008790.ref013]\]. However, the correlation between BMI and GRS in the Health and Retirement Study participants derived from Locke at.al., 2015 is near identical to the correlation between the BMI and GRS derived from Yengo et.al., 2018 (r = 0.22) \[[@pgen.1008790.ref032]\]. We are planning to generalize our study to these new GRS definitions in the near future. Also, our GRS definition is mainly based on SNPs found associated with BMI in adults and could be extended to include genetic variants more specific to children, taking advantage on recent GWAS discoveries \[[@pgen.1008790.ref033]--[@pgen.1008790.ref035]\].

Clinically, from a public health perspective, the promotion of EBF could play a pivotal role in the programming of healthy life trajectories since breast milk is the first postnatal nutritional environment of all mammals and is now widely recognized as essential for optimal infant growth and development \[[@pgen.1008790.ref036]\]. There is now widespread acceptance that the health benefits of breastfeeding continue well into the early childhood and beyond. The benefits for women have also been highlighted \[[@pgen.1008790.ref037]\]. The 2016 Lancet Breastfeeding Series quantified the impact of these health and development benefits on healthcare costs and economic growth reporting that increases in breastfeeding rates could save US\$400 million in health care costs in the US, UK, Brazil and China alone and inject US\$300 billion into economies from more a productive workforce \[[@pgen.1008790.ref038]\]. Despite these enormous benefits, only 40%, or two out of every five, infants globally are exclusively breastfed to 6 months postpartum as recommended. Successful breastfeeding programs directed at women are thus needed to achieve a longer duration of exclusive breastfeeding which, according to our findings, should be an important part of a comprehensive overweight or obesity prevention program to promote healthy growth trajectories during infancy that continue later in life.

While the benefits of breastfeeding on a healthy infant growth are well demonstrated, the biological functions underlying this effect are still poorly understood. The protective effect of breastfeeding could stem from its micronutrients and bioactive composition. Another hypothesis suggests the lower protein content of human milk compared with formula milk as the source of this protective effect \[[@pgen.1008790.ref039]\]. Understanding the biological mechanisms underlying the beneficial effect of breastfeeding on healthy growth warrants further investigations.
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Click here for additional data file.

###### Marginal effect of 2.5 units increase of GRS score on the age at adiposity peak (AP) and the age at adiposity rebound (AR).

The 95% confidence intervals (CIs) are computed with the bootstrap method3 with 2,000 iterations.

(DOCX)

###### 

Click here for additional data file.

###### Three-way interaction of cubic splines of age, GRS and breastfeeding (EBF: Exclusive breastfeeding, BF: Non-exclusive breastfeeding) for boys and girls.

The optimal knots were ($\mathcal{K}_{1} = 0.7$, $\mathcal{K}_{2} = 1.5$, $\mathcal{K}_{3} = 10$) for boys and ($\mathcal{K}_{1} = 0.9$, $\mathcal{K}_{2} = 1.5$, $\mathcal{K}_{3} = 10$) for girls. The knots were defined in supplementary file section A.2.

(DOCX)

###### 

Click here for additional data file.

###### Effect of 5 months of exclusive breastfeeding (EBF) and non-exclusive breastfeeding (BF) on BMI at 7, 10 15 and 18 years of age for GRS scores evaluated at 2.5, 5.0 and 7.5.

(DOCX)

###### 

Click here for additional data file.

###### Effect of 3 months and 5 months of exclusive breastfeeding (EBF) on the age at adiposity Peak (AP) and the age at adiposity rebound (AR) for GRS scores evaluated at 2.5, 5.0 and 7.5 and overall EBF effect regardless of GRS.

The 95% confidence intervals (CIs) are computed with the bootstrap method with 2,000 iterations.

(DOCX)

###### 

Click here for additional data file.

###### Effect of 3 months of exclusive breastfeeding (EBF) and non-exclusive breastfeeding (BF) on BMI measurements at 7, 10 15 and 18 years of age for GRS scores evaluated at 2.5, 5.0 and 7.5.

(DOCX)

###### 

Click here for additional data file.

###### Predicted BMI growth trajectories for ALSPAC Boys and Girls from birth to age 18 for GRS = 2.5, 5.0, or 7.5, and (a) EBF = 0 or 3 months, and (b) BF = 0 or 3 months.

(DOCX)

###### 

Click here for additional data file.

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and the Welcome Trust (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC.
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26 Jan 2020

Dear Dr Briollais,

Thank you very much for submitting your Research Article entitled \'Exclusive breastfeeding can attenuate body-mass-index increase among genetically susceptible children: a longitudinal study from the ALSPAC cohort\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Samuli Ripatti

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

There are multiple concerns raised by the Reviewers needs to be addressed and that prevent publication of the manuscript in its current form, in particular: 1) Please clarify what is the novelty of the current manuscript compared to the previous papers from ALSPAC and other data, 2) Please clarify the potential overlap of samples between the PRS weights and the test cohort and use other source for weights if they exist, and 3) present a formal statistical test for interaction as the basis for inference.

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: Thank you for the opportunity to review an interesting manuscript from effects of exclusive of breast feeding (EBF) and genetics on BMI trajectories. The Results section is clearly written and describes the age- and sex dependent complex relationships very well. However, there are some points which require clarification, especially the sample used to derive the SNP weights.

1\) What sample was used to derive the SNP weights for the GRS? Was there overlap with ALSPAC?

2\) Increased maternal BMI is a risk factor for emergency caesarean section and mode of delivery is associated for example with long-term changes in gut microbiota compared to vaginal delivery. As approximately half of the GRS is inherited from mother and thus affects also maternal BMI, could mode of delivery be a confounding factor?

3\) In the discussion, you suggest that obesity interventions could target subjects in the upper tail of GRS. What GRS percentile you would target? Could any intervention be effective enough to justify screening costs considering that by targeting upper tail most of the obesity cases are missed (in absolute numbers due to Rose paradox)? Why do you think that targeted intervention would be more reasonable approach than non-targeted one?

4\) Table 3: In boys, the effect of EBF on BMI seems to be larger when GRS is high. In girls, it seems to be the opposite (for example in 15 yo -1.55 if GRS=2.5 and -0.87 if GRS=7.5). Any suggestions why?

Reviewer \#2: The authors have performed a study on the association of exclusive breastfeeding with BMI, adiposity peak, and adiposity rebound in 5,266 children from the ALSPAC cohort, and the interaction of exclusive breastfeeding with a genetic risk score for increased BMI. The manuscript reports that exclusive breastfeeding reduces BMI in adolescents and attenuates the impact of a genetic risk score for BMI. While the results are interesting, the novelty of the study seems rather limited. The authors have previously published results from a similar analysis of the interaction between exclusive breastfeeding and the FTO obesity risk locus on BMI trajectories in the ALSPAC cohort \[29040503\]. The link between breastfeeding and child BMI has been previously studied in ALSPAC, by Brion et al. \[PMID 21349903\], although in somewhat less detail than here.

My other main comments are the following:

1\. The authors have used a weighted GRS, but the way the variants have been weighted when constructing the GRS is worrying. If I understand correctly, the effect sizes used for weighting were obtained from analyses of the ALSPAC dataset, i.e. the same dataset that was utilized in the present analyses. This leads to a bias where the effect of the GRS on BMI is inflated. To construct the GRS correctly, the weights would need to be extracted from the original GWAS discovery study or another large, independent dataset. Alternatively, an unweighted GRS could be used.

2\. The authors have combined results from 97 independent variants only, rather than taking advantage of more recent latest GWAS including \>400 independent variants \[PMID 30239722\].

3\. The authors state hat "the effect of the GRS is not well studied in children" (p. 3) and that "the role of the obesity-specific GRS remains largely unknown in children and adolescents" (p. 15). However, many studies of obesity-specific GRS in children have been published \[e.g. PMID 29211904, 30515969, 28008729, 24244521\]. Thus, these claims do not seem valid.

4\. The authors report having evaluated the interaction between the duration of exclusive breastfeeding and GRS on BMI growth trajectories. However, they have not performed a formal test for interaction, but rather base their conclusions on observing values between stratified subgroups, which does not seem sufficient statistical evidence for an interaction. The authors should perform a formal test for interaction by including an interaction term in the model. Similar issue applies to e.g. p. 14 where the authors state that "a duration of EBF for 3 months had significantly less impact in decreasing BMI than 5 months of EBF". A formal test for the difference between the groups should be included here, to make such claim about statistical significance.

Reviewer \#3: In this paper, the authors examine whether exclusive or any breastfeeding up until 5 months of age is protective against later BMI gain by BMI-associated genetic risk. The paper is in general well-written and the analyses are performed satisfactorily. Additionally, the findings are of broad public interest, and the conclusions are appropriate.

I do have some minor comments:

1\. It is fine to use only 97 BMI-associated variants, but then this choice should be justified, given that over 900 are now published that explain \~6% of the variance (Yengo HMG 2018). This should especially be considered in the Discussion, and perhaps expanding the GRS could be a \"future direction\".

2\. The abstract could use some clarification. Obesity is now better understood compared to what? I also find the second sentence unclear. Please also briefly add some detail about the GRS used in this study in the abstract, for example, how many SNPs, associated with adult or childhood BMI originally, etc.

3\. Is there a word \"and\" missing in the final sentence of the abstract, \"EBF influences early life growth AND development\"?

4\. It seems an overstatement to say that EBF plays a \"critical role\" based on this study\'s findings (only a 1.4kg/m2 decrease in BMI in boys at 18), but certainly EBF is important and has lifelong benefits on BMI gain, especially for those with high genetic load of increasing alleles.

5\. In the author summary, saying something is \"perfect\" is very subjective. Please rephrase using objective language.

6\. Author summary, last sentence: please change \"susceptibility alleles\" to \"increasing alleles\"

7\. Introduction, line 75: It is confusing and misleading to say that BF extends \"beyond healthy children, e.g., in children with higher genetic risks\". Kids with GRS for high BMI can still be healthy.

8\. Throughout the paper, please say \"pediatric BMI\" instead of \"child BMI\" since you are also talking about adolescents.

9\. Page 5, line 87: please add whether the GRS was weighted or unweighted

10\. Line 90: At what age did the GRS explain 1.5% of BMI variability?

11\. Page 8, line 146: Change \"principle\" to \"principal\"

12\. I question whether it makes sense to describe the equivalence of a 1-unit increase in GRS in terms of NUMBER of effect alleles carried given that the GRS was weighted..

13\. Page 9, line 174: \"maternal preconception\" is perhaps missing a word?

14\. Line 173: categorize \--\> categorizeD

15\. I think Table 2 and 3 would be easier to grasp with graphical representation, and put the data in these tables in the supplement. Why not give exact p-values in the table? Also please check the formatting\-- there should be a space after a numeral and before a parenthesis.

16\. Discussion, line 284: \"shed lights\" \--\> shed light

17\. Sentence on line 284 is confusing. I would remove \"The value of\" and \"in life\" \-- it is clearer without those

18\. Line 291: it \--\> they

19\. Top of page 16, please discuss why this GRS was used and not most recent data from Yengo et al included.

20\. Line 301: \"essential fluid\" sounds odd

21\. Finally, the English is overall good but requires careful editing by a native speaker. There are many small mistakes throughout.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.
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PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Dear Dr Briollais,

We are pleased to inform you that your manuscript entitled \"Exclusive breastfeeding can attenuate body-mass-index increase among genetically susceptible children: a longitudinal study from the ALSPAC cohort\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Samuli Ripatti

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics
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Comments from the reviewers (if applicable):

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The results presented in the manuscript are now on much more solid basis as the GRS weights are now derived from external data set. Luckily, this didn\'t change the results in a big picture. I have no more comments and I think that the manuscript should be considered for publication in Plos Genetics.

Reviewer \#2: The authors have addressed my comments appropriately. I have no further remarks.

Reviewer \#3: Thank you, all of my concerns have been addressed.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes
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PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: Yes: Diana L. Cousminer
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**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-20-00028R1>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.
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**Press Queries**

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.
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Dear Dr Briollais,

We are pleased to inform you that your manuscript entitled \"Exclusive breastfeeding can attenuate body-mass-index increase among genetically susceptible children: a longitudinal study from the ALSPAC cohort\" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Matt Lyles

PLOS Genetics

On behalf of:
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Carlyle House, Carlyle Road, Cambridge CB4 3DN \| United Kingdom
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[plosgenetics.org](http://plosgenetics.org) \| Twitter: \@PLOSGenetics
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